DanCann Pharma is presently in the process of formulating a new strategic roadmap aimed at propelling the Company toward success. This strategic reevaluation underscores the Company's commitment to addressing the evolving needs of its customers and stakeholders.

The Company has set its sights on achieving a revenue of approximately DKK 7 million within the current fiscal year, with plans for expansion in the subsequent year driven by the introduction of new products currently in development for the pipeline.

At present, DanCann Pharma is working to compile its first application, in accordance with the latest agreement reached with MYCB1. The Company is actively engaged in the preparation of the first two applications for the newly envisioned product format, centered around oral drops (oils).

Furthermore, DanCann Pharma has entered into several dialogues about the future for Biotech Pharm1 with interested parties. Both joint venture structures, and total takeovers are discussed in these dialogues.

DanCann Pharma will provide a comprehensive update on its new strategy and growth plans in October. This forthcoming announcement is anticipated to provide insights into the Company's vision for the future and its commitment to delivering value to its patients, customers and investors.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and side listed on OTCQB Venture Market in USA (OTCQB: DCPXF). For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Phone: +45 2963 6920

E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.